SAN DIEGO, April 3, 2017 /PRNewswire/ -- OncoSec
Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company
developing DNA-based intratumoral cancer immunotherapies, today
presented a poster titled "Intratumoral Delivery of a P2A-linked
Bicistronic IL-12 Construct Leads to High Intratumoral Expression
and Systemic Anti-tumor Response" (Abstract ID # 1614) at the
American Association of Cancer Research (AACR) Annual Meeting, in
Washington, D.C. The poster
included preclinical data demonstrating the latest developments of
OncoSec's gene delivery platform in a murine melanoma model.
Previous studies have shown the use of immunomodulatory
cytokines is effective in the regression of a wide range of tumors.
However, systemic delivery of recombinant cytokines has often
resulted in life-threatening adverse effects. Intratumoral gene
electrotransfer of plasmid encoded interleukin-12 (IL-12) has shown
acceptable safety and efficacy profiles in regressing tumors, both
preclinically and clinically.
"We sought to optimize the anti-tumor immune response of our
IL-12 immunotherapy platform that combines intratumoral injection
of plasmid DNA coding for IL-12 and electroporation. Using a mouse
model of melanoma, we were able to demonstrate that the changes
made to plasmid design and to electroporation parameters can
significantly increase production of IL-12, leading to an improved
anti-tumor effect," said Punit
Dhillon, OncoSec President and CEO. "The new IL-12 construct
is the backbone of our next generation combination molecules."
Copies of the abstract are available and can be viewed on the
AACR website at
http://www.abstractsonline.com/pp8/#!/4292/presentation/6375. The
poster is available in the Publications section of OncoSec's
website.
About OncoSec Medical Incorporated
OncoSec is a
biotechnology company developing DNA-based intratumoral
immunotherapies with an investigational technology,
ImmunoPulse®, for the treatment of cancer.
ImmunoPulse® is designed to enhance the local delivery
and uptake of DNA-based immune-targeting agents, such as IL-12. In
Phase I and II clinical trials, ImmunoPulse® IL-12 has
demonstrated a favorable safety profile and evidence of anti-tumor
activity in the treatment of various solid tumors as well as a
systemic clinical and immune response. OncoSec's lead program,
ImmunoPulse® IL-12, is currently in clinical development
for metastatic melanoma and triple-negative breast cancer. The
program's current focus is on the significant unmet medical need in
patients with melanoma who are refractory or non-responsive to
anti-PD-1/PD-L1 therapies. In addition to ImmunoPulse®
IL-12, the Company is also identifying and developing new
immune-targeting agents for use with the ImmunoPulse®
platform. For more information, please visit www.oncosec.com.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains "forward-looking
statements" within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995. Forward-looking statements can be
identified by words such as "can," "may," "will," "suggest," "look
forward to," "potential," "understand," and similar references to
future periods.
Forward-looking statements are neither historical facts nor
assurances of future performance. Instead, they are based on
management's current preliminary expectations and are subject to
risks and uncertainties, which may cause our results to differ
materially and adversely from the statements contained herein.
Potential risks and uncertainties that could cause actual results
to differ from those predicted include, among others, the
following: uncertainties inherent in pre-clinical studies and
clinical trials, such as the ability to enroll patients in clinical
trials and the risk of adverse events; unexpected new data, safety
and technical issues; our ability to raise additional funding
necessary to fund continued operations; and the other factors
discussed in OncoSec's filings with the Securities and Exchange
Commission.
Undue reliance should not be placed on forward-looking
statements, which speak only as of the date they are made. OncoSec
disclaims any obligation to update any forward-looking statements
to reflect new information, events or circumstances after the date
they are made, or to reflect the occurrence of unanticipated
events.
CONTACT:
Investor Relations:
OncoSec Medical Incorporated
855-662-6732
investors@oncosec.com
Media Relations:
DGI Comm
Laura Radocaj
212-825-3210
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/oncosec-presents-preclinical-data-demonstrating-improved-systemic-anti-tumor-response-following-modifications-to-il-12-gene-delivery-therapy-at-aacr-annual-meeting-300433210.html
SOURCE OncoSec Medical Incorporated